Other equities research analysts have also issued reports about the stock. BidaskClub upgraded shares of AxoGen from a “strong sell” rating to a “sell” rating in a report on Monday, November 25th. BTIG Research restated a “buy” rating and issued a $21.00 price objective on shares of AxoGen in a report on Monday, December 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. AxoGen has an average rating of “Buy” and a consensus target price of $25.00.
Shares of AXGN opened at $16.09 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.38 and a current ratio of 8.20. AxoGen has a fifty-two week low of $10.91 and a fifty-two week high of $25.84. The firm has a 50 day moving average price of $17.02 and a 200-day moving average price of $15.92.
AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.04. The firm had revenue of $28.56 million during the quarter, compared to analyst estimates of $28.10 million. AxoGen had a negative net margin of 26.79% and a negative return on equity of 17.82%. Equities analysts expect that AxoGen will post -0.69 earnings per share for the current year.
Several institutional investors and hedge funds have recently made changes to their positions in AXGN. Advisor Group Inc. lifted its holdings in shares of AxoGen by 86.3% in the 2nd quarter. Advisor Group Inc. now owns 2,548 shares of the medical equipment provider’s stock worth $51,000 after acquiring an additional 1,180 shares during the last quarter. Wells Fargo & Company MN raised its holdings in AxoGen by 3.1% during the 2nd quarter. Wells Fargo & Company MN now owns 302,835 shares of the medical equipment provider’s stock valued at $5,996,000 after buying an additional 9,004 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in AxoGen by 17.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 12,260 shares of the medical equipment provider’s stock valued at $239,000 after buying an additional 1,854 shares during the last quarter. Bank of Montreal Can raised its holdings in AxoGen by 82.6% during the 2nd quarter. Bank of Montreal Can now owns 6,595 shares of the medical equipment provider’s stock valued at $131,000 after buying an additional 2,984 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in AxoGen by 2.4% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 199,723 shares of the medical equipment provider’s stock valued at $3,955,000 after buying an additional 4,590 shares during the last quarter. Hedge funds and other institutional investors own 82.94% of the company’s stock.
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
See Also: Google Finance Portfolio
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.